# A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

Source: https://onco.cc/trials/nct07807163/  
OnCo record `nct07807163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ficerafusp alfa, Pembrolizumab in head and neck squamous cell carcinoma, run by Bicara Therapeutics, now recruiting.

## Summary

A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC is a phase 2 interventional study registered as NCT07807163 by Bicara Therapeutics, with 160 participants planned, started 2026-09 and due to reach its primary completion in 2028-03. Interventions recorded: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®). Conditions listed: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07807163
- Phase: 2
- Setting: A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Bicara Therapeutics
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07807163: https://clinicaltrials.gov/study/NCT07807163

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Ficerafusp alfa](https://onco.cc/drugs/ficerafusp-alfa/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Bicara Therapeutics](https://onco.cc/companies/bicara-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07807163.json